fate therapeutics is applying leading expertise in stem cell biology and conventional drug discovery to develop small molecule and biologic drugs that: 1) activate stem cells in the body to stimulate healing and repair or block cancer growth; and 2) create and differentiate "pharmaceutical grade" ips cells to enable their use in drug discovery and development, disease modeling, and eventually personalized cell therapies. the company’s approach has broad therapeutic potential in areas such as regenerative medicine, hematological diseases, metastatic cancer, traumatic injury and degenerative diseases.
![Fate Therapeutics logo](/files/LOGO/1434316-FATE.png)
Company profile
Ticker
FATE
Exchange
Website
CEO
John Wolchko
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Fate Therapeutics (UK) Ltd. • Tfinity Therapeutics, Inc. • Fate Therapeutics B.V. • Senescea Therapeutics, Inc. ...
FATE stock data
Latest filings (excl ownership)
S-8
Registration of securities for employees
10 Jun 24
8-K
Amendments to Articles of Incorporation or Bylaws
10 Jun 24
8-K
Departure of Directors or Certain Officers
7 Jun 24
8-K
Departure of Directors or Certain Officers
31 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Fate Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
9 May 24
8-K
Fate Therapeutics Announces First Lupus Patient Treated in Phase 1 Autoimmunity Study of Off-the-shelf FT819 CAR T-cell Program
9 May 24
424B3
Prospectus supplement
2 May 24
EFFECT
Notice of effectiveness
30 Apr 24
ARS
2023 FY
Annual report to shareholders
26 Apr 24
Transcripts
FATE
Earnings call transcript
2024 Q1
9 May 24
FATE
Earnings call transcript
2023 Q4
26 Feb 24
FATE
Earnings call transcript
2023 Q3
8 Nov 23
FATE
Earnings call transcript
2023 Q2
8 Aug 23
FATE
Earnings call transcript
2023 Q2
8 Aug 23
FATE
Earnings call transcript
2023 Q1
3 May 23
FATE
Earnings call transcript
2022 Q4
28 Feb 23
FATE
Earnings call transcript
2022 Q3
4 Nov 22
FATE
Earnings call transcript
2022 Q2
4 Aug 22
FATE
Earnings call transcript
2022 Q1
5 May 22
Financial summary
Quarter (USD) | Mar 24 | Dec 23 | Sep 23 | Jun 23 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 136.50 mm | 136.50 mm | 136.50 mm | 136.50 mm | 136.50 mm | 136.50 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.02 mm | 17.75 mm | 11.12 mm | 11.40 mm |
Cash used (since last report) | n/a | n/a | 65.81 mm | 68.62 mm | 42.98 mm | 44.06 mm |
Cash remaining | n/a | n/a | 70.69 mm | 67.88 mm | 93.52 mm | 92.44 mm |
Runway (months of cash) | n/a | n/a | 4.2 | 3.8 | 8.4 | 8.1 |
Institutional ownership, Q1 2024
13F holders | Current |
---|---|
Total holders | 160 |
Opened positions | 147 |
Closed positions | 6 |
Increased positions | 4 |
Reduced positions | 3 |
13F shares | Current |
---|---|
Total value | 871.41 bn |
Total shares | 121.23 mm |
Total puts | 48.60 k |
Total calls | 221.80 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
Redmile | 13.17 mm | $96.66 bn |
Vanguard | 9.91 mm | $72.75 bn |
BLK Blackrock | 9.10 mm | $66.79 bn |
Boxer Capital | 8.22 mm | $60.30 bn |
STT State Street | 8.04 mm | $58.99 bn |
Deep Track Capital | 5.57 mm | $40.90 bn |
BLVGF Bellevue | 4.84 mm | $35.52 bn |
JNJ Johnson & Johnson | 3.38 mm | $24.80 bn |
Citadel Advisors | 3.13 mm | $22.99 bn |
MS Morgan Stanley | 3.07 mm | $22.50 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
7 Jun 24 | Mendlein John | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 40,000 | 147.20 k | 40,000 |
7 Jun 24 | Epstein Robert S | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 40,000 | 147.20 k | 40,000 |
7 Jun 24 | Agarwal Shefali | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 40,000 | 147.20 k | 40,000 |
7 Jun 24 | Yuan Xu | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 40,000 | 147.20 k | 40,000 |
7 Jun 24 | Coughlin Timothy | Stock Option Common Stock | Grant | Acquire A | No | No | 3.68 | 40,000 | 147.20 k | 40,000 |
News
Why Charles Schwab Shares Are Trading Lower By Over 7%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
16 Jul 24
UnitedHealth Posts Better-Than-Expected Earnings, Joins AngioDynamics, Bank of America And Other Big Stocks Moving Higher On Tuesday
16 Jul 24
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
17 Jun 24
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
17 Jun 24
Piper Sandler Upgrades Fate Therapeutics to Overweight, Raises Price Target to $6
17 Jun 24
Press releases
FATE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Fate Therapeutics, Inc. (NASDAQ: FATE) and Encourages Long-Term FATE Investors to Contact the Firm
13 Jun 24
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
4 Jun 24
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
29 May 24
Fate Therapeutics Announces Presentation of FT522 Preclinical Data for Autoimmune Diseases in Late-breaking Abstract at ASGCT Annual Meeting
3 May 24